Status
Terminated
Drug Enforcement D-0758-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Classification
Class II
Report Date
May 31, 2023
Termination Date
September 6, 2024
Product Information
- Product description
- Glimepiride Tablets, USP, 2 mg, RX, Packaged as a ) 100-count bottle, NDC# 68001-178-00; b) 500-count bottle; NDC# 68001-178-03 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. For BluePoint Laboratories
- Product quantity
- 105,361 bottles
- Reason for recall
- CGMP Deviations: recalling drug products following an FDA inspection.
- Recall initiation reason
- —
- Initial firm notification
- Letter
- Distribution pattern
- Nationwide USA
Location & Firm
- Recalling firm
- Amerisource Health Services LLC
- Address
-
2550 John Glenn Ave Ste A, N/A
United States - Voluntary / Mandated
- Voluntary: Firm initiated
- Status date
- —
Codes & Dates
- Recall number
- D-0758-2023
- Event ID
- 92058
- Recall initiation date
- March 17, 2023
- Center classification date
- May 19, 2023
- Code info
- Batches a)P2003493, EXP 05/31/2023; P2100120, EXP 11/30/2023; P2100683, EXP 01/31/2024; P2106002, EXP 07/31/2024; R2200148, EXP 12/31/2024; R2201125, EXP 06/30/2025 b) P2003403, EXP 05/31/2023; b) P2005800, EXP 09/30/2023; P2101156, EXP 01/31/2024; P2105401, EXP 07/31/2024; R2200083, EXP 12/31/2024; R2201004, EXP 07/31/2025
- More code info
- —